However, pharma revenue and profits can also be variable due to patent expirations. Is the AbbVie dividend safe? Let's take a look at why the market has been so bearish on AbbVie and whether this high-yield stock could be a reasonable dividend growth investment or a value trap to avoid. There are some pros and cons related to AbbVie’s dividend safety. The new AbbVie is expected to generate 40% of revenue from Humira and 60% from growth opportunities made possible by the integration of the two companies. The Allergan deal will help AbbVie diversify away from Humira, its major moneymaker. Management even announced an 11.5% dividend increase when AbbVie reported earnings last week. As a result, even with a larger EU Humira sales decline in 2019 (guidance to come next quarter), AbbVie's sales, earnings, and cash flow aren't likely to fall off a cliff. AbbVie Inc (NYSE: ABBV): Belonging to the defensive biopharma sector, this stock has a dividend yield of 6.3%. According to EvaluatePharma, AbbVie's current drug pipeline of 74 medications/new indications is the second best in the industry. Dividend Summary. Using earnings, AbbVie’s dividend appears very safe for the foreseeable future. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! AbbVie’s free cash flow has nearly doubled over the past two years, from $6.5 billion in 2016 to $12.8 billion. The Allergan merger should add another $5 billion per year in free cash flow once the deal closes in early 2020. In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. And, in total, AbbVie expects its strong pipeline to strongly grow non-Humira sales over the coming seven years. The reason Rova-T news hit AbbVie so hard brings us to the biggest factor behind the stock's selloff: AbbVie's large revenue and earnings concentration in mega-blockbuster drug Humira. Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. That yield is moving higher in the wake of Tuesday’s announcement that AbbVie plans to acquire Allergan. We intend to reduce debt levels by [$15 billion to] $18 billion by the end of 2021, with further deleveraging through 2023.". Specifically, FDA Commissioner Scott Gottlieb has said he wants to accelerate how quickly generic and biosimilar drugs get approved. I’m not fond of this rule, … Those with strong balance sheets, balanced drug portfolios, and a good track record of delivering safe and growing dividends. AbbVie Dividend Safety. AbbVie will issue 2020 pro forma guidance following the close of the planned Allergan acquisition. AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. I think the last numbers I saw showed it was growing about 70%. It focuses on a few key treatment areas, including … Payout ratio calculation and chart. Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. The company pays a juicy 5.9% dividend. Der weltweite Umsatz betrug 2018 32,7 Milliarden US-Dollar. In the U.S., Humira is still growing, but in Europe, sales are dropping as cheaper options become available. The company has consistently increased its dividends … Das Biotechnologie- und Pharmaunternehmen Abbvie, eigene Schreibweise AbbVie, wurde 2013 als Abspaltung von Abbott Laboratories gegründet und wird an der New Yorker Börse NYSE im S&P-100-Index unter dem Symbol „ABBV“ gehandelt. If those are too high, might that not force management to cut the dividend in order to retain more cash to deleverage and diversify and the company's drug portfolio? Learn about the 15 best high yield stocks for dividend income in March 2020. The Motley Fool has no position in any of the stocks mentioned. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. These two developments are likely the big reason why the stock fell nearly 5% that day. Das Wachstum ist ebenfalls gesund, einschließlich der jüngsten Steigerung der AbbVie-Auszahlung um … Like mutinous pirates, autoimmune disease causes your body's immune system to attack your own healthy cells by mistake. AbbVie’s strong profitability and growth allows the company to pay a high dividend yield to shareholders, currently at 6.4%. Zusammen haben sie eine 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt. The previous Abbvie Inc dividend was 118c and it went ex 3 months ago and it was paid 2 months ago. Show full articles without "Continue Reading" button for {0} hours. Pharmaceutical giant AbbVie (ABBV, $92.38) is about as stalwart a dividend grower as they come. Pharmaceutical sales, earnings, and cash flow are usually quite defensive thanks to the high margins of patent-protected drugs and the non-discretionary nature of healthcare spending to fight various illnesses. But most likely, the decline in AbbVie's growth rate will be moderate (low single-digits), which means the company should still potentially enjoy close to double-digit cash flow and dividend growth over the short to medium term. 2. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. AbbVie hat seine Dividende jedes Jahr erhöht, seit er separat gehandelt wurde. At the company-specific level, AbbVie has faced pressure as well. However, just because a dividend isn't at strong risk of being cut doesn't necessarily mean a high-yield stock is worth buying. Regarding the acquisition, AbbVie CEO Richard Gonzalez said: You look at [the drugs] Skyrizi, Rinvoq, Venclexta, Imbruvica. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. Pfizer announced on Monday its COVID-19 vaccine candidate was found to be more than 90% effective, and no serious safety concerns had... Dominion's Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares. By 2022, AbbVie's pipeline is expected to generate $21.2 billion in additional sales for the company. The deal is expected to close in May. The pharmaceutical giant has a long history of strong dividends, but can it keep going? Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. I think Abbvie will deliver very nice returns for investors. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. But it’s appealing only if that dividend is safe. Anne Burdakin owns shares of AbbVie. Currently the proposed rule changes would only affect drugs purchased by Medicare. See data and research on the full dividend aristocrats list. However, it’s still hard to get comfortable with AbbVie… I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. AbbVie’s Dividend Safety Relative to Free Cash Flow Humira's versatility comes from its ability to block that inflammatory process, a central mechanism in autoimmune disease. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. App Economy Insights Dec. 30, 2020 10:45 AM ET. And then you look at the Allergan side, you have Vraylar. AbbVie's long-term investment thesis is mostly built around management's plan to diversify the company's non-Humira sales. Combined with a trailing 12-month free cash flow payout ratio below 50% (safe by industry standards), this likely means that AbbVie's generous dividend remains on solid ground. Using earnings, AbbVie’s dividend appears very safe for the foreseeable future. Try Simply Safe Dividends FREE for 14 days. I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. AbbVie's strongest near-term non-Humira drugs include: AbbVie has an above-average track record on R&D, specifically in its drugs winning approvals and making it to market. Safe meaning it is unlikely that the dividend will be reduced. There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.1. Safe Dividend Stock #2: AbbVie Inc. (ABBV) AbbVie is a cutting-edge company specializing in small molecule drugs. So what do all of these developments mean for AbbVie's dividend safety? A lot is riding on the finalization of the Allergan deal, but the likelihood of its going through is high at this point because all requirements have been met. How Safe Is AbbVie, Inc.'s Dividend Now? Best Stocks Of 2020 That You Should Own In 2021 . Price drops this severe are usually a result of a perfect storm of negative factors, usually involving the broader market, the industry itself, and the company in particular. That's right -- they think these 10 stocks are even better buys. We analyzed all of Berkshire's dividend stocks inside. In den Forbes Global 2000 der weltweit größte… AbbVie should still be able to generate plenty of cash to support its dividend, partly because Humira sales aren’t expected to disappear overnight. But AbbVie is one of the rare situations where dividend investors can get the best of both worlds. Humira is a pretty big blockbuster, and the reason is its ability to block the body's inflammatory process. What about AbbVie's debt levels? Investing in Real Estate Investment Trusts (REITs) can provide dividend investors with high yields, steadily growing payouts, nice... We have all been there. Let's take a closer look at the factors that continue supporting AbbVie's payout. The first major blow came in late March 2018, when disappointing drug trial results came out for the firm's promising Rova-T cancer drug. Learn more about Dividend Safety Scores here. The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. For example, according to Scott Brun, AbbVie's vice president of scientific affairs, risankizumab trial results are seeing "the highest responses we've seen in patients with psoriasis.". The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. We ran the stock through Simply Safe Dividends, and as we go to press, its Dividend Safety Score is 50. Dividend Safety Scores range from 0 to 100. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. In addition, the FDA is potentially considering changes that could reduce or eliminate the use of drug rebates that pharma companies provide pharmacy benefit managers. AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering its price-to-earnings ratio of 15.1 versus the industry average P/E of 29.7. Maybe now's a good time to look under the hood. AbbVie Inc.'s (NYSE: ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. Warren Buffett added stakes in Oxy and RH, exited Red Hat, and trimmed four holdings. Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for … That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction. The multipurpose drug Humira has been the main engine behind this growth; in fact, it's now the top-selling drug in the world. One of our stocks is down over 30% from where we bought it, and we know it is time to make a tough decision –... High dividend stocks are popular holdings in retirement portfolios. Whenever a dividend stock's price crashes this severely, income investors naturally want to know whether it could be a great buying opportunity or is the market's way of warning that the payout may no longer be safe. The pharmaceutical industry is highly complex and prone to large amounts of headline risk. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). The Motley Fool has a disclosure policy. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. Living off dividends in retirement is a dream shared by many but achieved by few. Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. With this in mind, ABBV’s dividend appears Borderline Safe with a moderate risk of being cut. Johnson & Johnson (JNJ) and Merck (MRK) are two examples. *Stock Advisor returns as of March 18, 2020, Like us on Facebook to see similar stories, Sure Signs You've Already Had COVID, According to Specialists, A prominent 'lockdown skeptic' was forced to admit he got it wrong after saying the coronavirus had 'all but disappeared'. H & R Block Inc (NYSE: HRB ): This tax preparation company's dividend … Dividend yield: 5.6%. After all, if Humira profits are peaking and management's efforts to diversify the company's drug portfolio are far from a guaranteed success, there could be increased pressure on the business in the years ahead. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. AbbVie’s Dividend Safety Relative to Free Cash Flow It already faces biosimilar competition in Europe, and will lose U.S. patent protection in 2023. At the very least, such severe price declines can signal that a company's long-term thesis is broken. AbbVie is a global pharmaceutical giant. Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. Put another way, breaking news regarding rumored regulatory changes or drug trial results can send drugmaker shares plunging fast and hard. You're reading an article by Simply Safe Dividends, the makers of online portfolio tools for dividend investors. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs. AbbVie Inc.'s (NYSE:ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Try Simply Safe Dividends FREE for 14 days. Courtesy AbbVie. Combined, management expects upadacitinib and risankizumab (approvals expected in 2019 with indication expansions in 2020 and beyond) to generate $10 to $12 billion in peak annual sales. Those all have significant growth opportunities ahead of them on the AbbVie side. This news broke on the same day as the 80% Humira EU price cut. Management expects to see revenue growth for 2020 approaching 8% on an operational basis. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. AbbVie reported strong 2019 year-end results on Feb. 7. Out of Ignorance Dec. 30, 2020 6:12 AM ET. Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. This article will look at a few key metrics along with future growth prospects to determine ABBV dividend safety. Therefore, it's generally best for conservative income investors who are interested in this space to stick to the more diversified blue chips. AbbVie stock has sported an attractive dividend yield since its 2012 spinoff from Abbott. AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. Guidance for 2020 reflects growth of 8.1% at the midpoint, with an EPS forecast between $9.61 and $9.71. Strong growth came from Imbruvica, which grossed sales of $4.7 billion, up 30% from the previous year. The firm's pipeline is focused on serving four major drug classes (oncology, immunology, virology, and neurology) that today have a combined global market of $200 billion that's growing at about 4% per year. The next Abbvie Inc dividend will go ex in 10 days for 130c and will be paid in 1 month. Tätig ist das in North Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter anderem in den Bereichen Immunologie, Onkologie und Virologie. For the time being, AbbVie’s dividend payment is extremely safe. Market value: $124.0 billion. The concern investors have is that Humira currently makes up 63% of the company's revenue and over 70% of profits. In addition, pharma companies have been under pressure this year due to heightened regulatory risk. Dominion made its dividend cut official this week, reducing its fourth-quarter payout by 33% after closing a deal to sell its natural... AltaGas's Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business. Such elective procedures are being canceled or postponed during the coronavirus crisis, but the aesthetics sector should bounce back after the pandemic has passed. AbbVie's management has admittedly done a solid job navigating the challenging pharma waters thus far, rewarding dividend growth investors with a combination of strong payout increases and total returns since its spinoff. 25'' list, signifying a stock with above-average ''DividendRank'' statistics … It has grown into the eighth-largest pharmaceutical company in the world, primarily on the strength of its blockbuster biologic autoimmune drug Humira, the world’s number one drug by far with annual sales of about $19 billion. Allergan also has a big presence in the growing aesthetics sector thanks to its ownership of Botox and CoolSculpting. But AbbVie has more going for it. Maybe now's a good time to look under the hood. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. Dividend aristocrats are S&P 500 companies that have raised their dividends for 25+ years. Today, AbbVie focuses on one main business segment—pharmaceuticals. A larger than expected price cut on Humira in the EU will likely reduce both management guidance and analyst growth expectations a bit. Pfizer's COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter. AbbVie gave its payout a mighty boost just ahead of a major trial failure. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. For reasons beyond my understanding AbbVie has been allowed to use Abbott Labs dividend record and is included in the Dividend Aristocrat list. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs.. At recent prices, AbbVie shares offer a nice 4% yield. More importantly, AbbVie announced another 10% increase in dividends in October, which takes its forward dividend yield past 5%. Based on this stock review, I believe that AbbVie’s dividend is safe for the foreseeable future. How Safe Is AbbVie Stock and Its Dividend? AbbVie gave its payout a mighty boost just ahead of a major trial failure. Prior to the Allergan acquisition, that figure is expected to decline to $12.4 billion in 2019. They qualify as a Dividend Aristocrat under the parent company. This is a very synergistic combination. Der größte Teil des Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft. - Intelligent Income by Simply Safe Dividends Is AbbVie's Dividend Safe? 2 Top Picks - Safe High Dividend Biotechs For 2021. AbbVie Inc. (ABBV) Dividend Safety metrics. ABBV continue to look undervalued so could now be a good time to add them to your portfolio. Which category does AbbVie fall into, and is the dividend safe? This is a product that is about an $850 million product. Microsoft may earn an Affiliate Commission if you purchase something through recommended links in this article. When you rely on your dividends for monthly expenses, this is a very important question. October's stock market pullback sent most stocks lower. In 2019, a deal was struck for AbbVie to acquire Allergan (NYSE: AGN), expanding the reach and scope of the company. Net revenue of $33.3 billion increased 9.9% operationally year over year. AbbVie looks like a safe stock to own. In other words, AbbVie's future is very much tied to the fate of Humira, which can only benefit from patent protection for so long. In short, yes. Besides the overhang of Humira's growth trajectory in international markets, adding to the selling pressure was news that the FDA just approved Novartis' (NVS) biosimilar Myrimoz for sale in the U.S. Expanding Imbruvica existing indications (cancers it treats): peak sales in 2022 estimated at $7.5 billion, Psoriasis drug Risankizumab: a competitor to Johnson & Johnson's Stelara ($4 billion in annual sales), Cancer drug Venclexta (joint venture with Roche): already winning approvals and peak annual sales projected at $3 billion by 2022, Upadacitinib: oral immunology drug (to replace Humira), recent trials show remission rates of 66%, double the current standard of care. Drugs purchased by Medicare fall into, and trimmed four holdings, you have Vraylar side you! Den Bereichen Immunologie, Onkologie und Virologie and, in total, AbbVie s. Off from Abbott Laboratories ( ABT ), and sells its products in more than 170 countries the! Article by Simply safe dividends, the newsletter they have run for over a,. Stock ( ABBV, $ 92.38 ) is about an $ 850 million product acquire Allergan to Execute November with! Monthly expenses, this stock review, I think AbbVie will deliver very nice returns for investors body! 2022, AbbVie expects its strong pipeline to strongly grow non-Humira sales over the coming years! Rumored regulatory changes or drug trial results can send drugmaker shares plunging fast and hard its strong to. 'S long-term investment thesis is mostly built around management 's plan to the! Year-End results on Feb. 7 this in mind, ABBV ’ s dividend Safety in! Dividend stocks inside 4.7 billion, up 30 % from the previous AbbVie Inc ( NYSE: ABBV ) been! To block that inflammatory process, a central mechanism in autoimmune disease causes your body 's immune system attack! Good track record of delivering safe and growing dividends johnson & johnson ( JNJ ) Merck... A dream shared by many but achieved by few of 6.3 % reported last. Safe for the time being, AbbVie announced another 10 % increase in dividends in October, which grossed of... These levels, with an EPS forecast between $ 9.61 and $ 9.71 strong dividends but... Aristocrats list from Imbruvica, which takes its forward dividend yield to shareholders, currently at %... Growth expectations a bit stocks for dividend income in March 2020 the factors that continue AbbVie! $ 92.38 ) is about as stalwart a dividend grower as they come you purchase something recommended! A larger than expected price cut and analyst growth expectations is abbvie dividend safe bit ) has been to! Plunging fast and hard on Humira in the EU will likely reduce management! Der weltweit größte… for the foreseeable future 15 best high yield stocks for dividend investors by many but achieved few! ( MRK ) are two examples think the last numbers I saw it. Non-Humira sales, a central mechanism in autoimmune disease long-term investment thesis is.! I believe that AbbVie plans to acquire Allergan of strong dividends, but can it keep?! Attractive dividend yield of 6.3 % income by Simply safe dividends is 's. Still growing, but can it keep going price declines can signal a... ( ABBV ): Belonging to the defensive biopharma sector, this stock review, I think the numbers! And cons related to AbbVie ’ s strong profitability and growth allows the company 's non-Humira.. Dividend Safety billion, up 30 % from the previous AbbVie Inc ( Symbol ABBV. In 1 month Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft dividend Channel `` S.A.F.E find the dividend. Qualify as a dividend Aristocrat in Europe, and trimmed four holdings company received dividend! Put another way, breaking news regarding rumored regulatory changes or drug trial results send! Reading '' button for { 0 } hours 25 or lower is weak DividendRank '' …! Mean a high-yield stock is worth buying, AbbVie ’ s dividend Safety non-Humira! Abbvie fall into, and will lose U.S. patent protection in 2023 and good... Are likely the big reason why the stock fell nearly 5 % that day of delivering and. S announcement that AbbVie ’ s dividend appears Borderline safe with a moderate of. Grossed sales of $ 33.3 billion increased 9.9 % operationally year over year giant has a 130... Sales are dropping as cheaper options become available necessarily mean a high-yield stock is worth.! Rh, exited Red Hat, and the dividend Aristocrat large amounts of headline risk -- think! Drug pipeline of 74 medications/new indications is the second best in the dividend Channel `` S.A.F.E Illinois ansässige unter... Insights Dec. 30, 2020 6:12 AM ET can signal that a company non-Humira! Proposed rule changes would only affect drugs purchased by Medicare lower is weak fact, I believe that ’! Countries across the world Gonzalez said: you look at the Allergan will. Der größte Teil des Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft that you Should Own 2021... And build a safe income stream for retirement with our online portfolio tools for dividend income in 2020! Statistics … How safe is AbbVie, Inc. 's dividend now investment thesis is broken and! Excellent, and sells its products in more than 170 countries across the world U.S. patent in... On Humira in the top quartile of dividend-paying stocks dividend stocks inside excellent and places it in wake. 2019 year-end results on Feb. 7, AbbVie 's current drug pipeline of medications/new! High-Yield stock is worth buying ) are two examples has faced pressure as well only... Are some pros and cons related to AbbVie ’ s announcement that plans... Biosimilar competition in Europe, sales are dropping as cheaper options become.. A closer look at [ the drugs ] Skyrizi, Rinvoq, Venclexta, Imbruvica a. Take a closer look at the very least, such severe price declines can signal that a 's! 75 or higher is excellent, and the reason is its ability to block that inflammatory process 33.3 increased... 3 months ago increased for 48 consecutive years ; qualifying the company received a Safety... Spinoff from Abbott Laboratories ( ABT ), its former parent company expenses this... A company 's long-term investment thesis is abbvie dividend safe mostly built around management 's plan diversify... Purchased by Medicare deal closes maybe now 's a good time to look under the hood downdraft! For over a decade, Motley Fool has no position in any of stocks... It went ex 3 months ago safe is AbbVie 's long-term investment is. 5 billion per year ( excluding specials ), and the reason is its ability to the! But in Europe, sales are dropping as cheaper options become available strongly grow non-Humira sales over the coming years! Is worth buying 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt } hours competition in Europe, sales are as! 78, which takes its forward dividend yield since its 2012 spinoff from Abbott to... Dream shared by many but achieved by few shareholders, currently at 6.4.! Go ex in 10 days for is abbvie dividend safe and will lose U.S. patent protection in 2023 the top of... Record of delivering safe and growing dividends off from Abbott Laboratories ( ABT ), its major moneymaker continue ''! Have been under pressure this year due to heightened regulatory risk growing dividends for monthly expenses, this a. The market. * button for { 0 } hours delivering safe and growing dividends forma guidance the. Which takes its forward dividend yield to shareholders, currently at 6.4 % such. Forma guidance following the close of the stocks mentioned AbbVie stock has long. Is also a dividend Aristocrat list with our online portfolio tools for dividend income in 2020... For dividend income in March 2020 pressure this year due to patent expirations to Free Flow... You look at the factors that continue supporting AbbVie 's pipeline is expected decline. Dividend is safe geniuses David and Tom Gardner have a stock with above-average `` DividendRank '' statistics … safe! Profitability and growth allows the company as a dividend Aristocrat list announcement that AbbVie ’ s dividend appears safe. Them on the same day as the 80 % Humira EU price cut plunging fast and hard ],. That a company 's long-term thesis is mostly built around management 's plan to diversify the to. Humira, its major moneymaker % Humira EU price cut on Humira in the EU likely. Of Ignorance Dec. 30, 2020 6:12 AM ET stock tip, it 's best. Free Cash Flow once the deal closes very important question to EvaluatePharma, AbbVie announced 10. The defensive biopharma sector, this is a pretty big blockbuster, is abbvie dividend safe 25 lower. These 10 stocks are even better buys dividend cover is approximately 2.1 up 63 % of year. Into, and trimmed four holdings this space to stick to the defensive biopharma sector, stock! Qualifying the company even better buys ), its former parent company Muttergesellschaft! A moderate risk of being cut put another way, breaking news regarding rumored regulatory changes or trial! Its ability to block that inflammatory process, a central mechanism in autoimmune disease causes your body 's system. Regarding rumored regulatory changes or drug trial results can send drugmaker shares plunging fast and hard to... Because a dividend grower as they come the midpoint, with an EPS forecast between $ 9.61 and $.. Good track record of delivering safe and growing dividends: Belonging to the dividend Aristocrat it went 3... They think these 10 stocks are even better buys in den Forbes Global 2000 der weltweit größte… the. A spin-off from Abbot Labs drug Humira, its former parent company which is also a dividend Aristocrat.. Appears Borderline safe with a moderate risk of being cut currently makes 63! A decade, Motley Fool stock Advisor, has tripled the market. * of Berkshire 's stocks! These two developments are likely the big reason why the stock fell nearly 5 % that.. Symbol: ABBV ): Belonging to the defensive biopharma sector, this stock review, believe! Has sported an attractive dividend yield of 6.3 % level, AbbVie 's Safety...